

--53. (New) The method of claim 1, wherein the fragment is up to 100 amino acids in length.

54. (New) The method of claim 53, wherein the fragment is up to 50 amino acids in length.

55. (New) The method of claim 1, wherein the fragment is at least 50 amino acids in length.

56. (New) The method of claim 1, wherein the fragment is at least 100 amino acids in length.

57. (New) The method of claim 1, wherein the fragment is at least 200 amino acids in length.

58. (New) The method of claim 1, wherein the fragment comprises at least one type I repeat or functional fragment thereof.

59. (New) The method of claim 1, wherein the fragment includes between about 5 to 50 amino acids of a type I repeat.

60. (New) The method of claim 1, wherein the fragment comprises at least one sequence selected from the group of: amino acids 382-429 of SEQ ID NO:2, amino acids 438-490 of SEQ ID NO:2, and amino acids 495-547 of SEQ ID NO:2, or a functional fragment thereof.

61. (New) The method of claim 1, wherein the fragment comprises SEQ ID NO:11.

62. (New) The method of claim 1, wherein the fragment consists of SEQ ID NO:11.

63. (New) The method of claim 1, wherein the fragment comprises a procollagen domain or a functional fragment thereof.

64. (New) The method of claim 63, wherein the fragment comprises SEQ ID NO:6.

65. (New) The method of claim 63, wherein the fragment comprises SEQ ID NO:7.

66. (New) The method of claim 63, wherein the fragment comprises SEQ ID NO:8.

67. (New) The method of claim 63, wherein the fragment comprises SEQ ID NO:9.

68. (New) The method of claim 1, wherein the fragment comprises a fragment of SEQ ID NO:10 at least 4 amino acids in length.

69. (New) A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising administering a polypeptide comprising a TSP-2 type I domain or a functional fragment thereof.

70. (New) The method of claim 69, wherein the fragment is at least 50 amino acids in length.

71. (New) The method of claim 69, wherein the fragment is at least 100 amino acids in length.

72. (New) A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising administering a TSP-2 procollagen region or a biologically active fragment thereof.

73. (New) The method of claim 72, wherein the fragment is at least 50 amino acids in length.

74. (New) The method of claim 72, wherein the fragment is at least 100 amino acids in length.--

ADD
C9